Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      SurvivorLink Pairs Young Breast Cancer Patients With Mentors Who Understand

      April 25, 2014
      Article

      Take it from young women who've been there-sometimes you just want to talk to someone who's been there, too.

      Take it from young women who’ve been there—sometimes you just want to talk to someone who’s been there, too. The Young Survival Coalition’s SurvivorLink peer mentoring program helps young women facing breast cancer find the priceless support, wisdom, and understanding that only a fellow survivor can provide.

      This supportive program welcomes women at all stages of breast cancer, because—whether you just received your diagnosis or have been proudly fighting for years—the voice of someone who’s walked the same path can be the most welcome gift in the world.

      We’ll help you find support from young women who understand where you are: a single woman who can share her thoughts about facing a mastectomy, a fellow Latina who wants to talk about cultural issues, a woman living with metastatic breast cancer, a young mother who needs to talk about what recurrence might mean for her children—all of these women and more can find support through SurvivorLink.

      Women from all backgrounds volunteer as empathetic listeners, including, for example, those who:

      • were diagnosed in their early 20s
      • are partnered with other women
      • have had chemotherapy while pregnant
      • live with metastatic disease
      • are estrogen receptor +/- or HER2+
      • have had a double mastectomy or an oophorectomy
      • are triple negative

      Start Talking

      We will focus on your interests and concerns so we can find the best peer match for you among our network of courageous and compassionate young women.Within 48 hours, a match with a trained SurvivorLink volunteer will occur, and she will contact you for an informal talk by phone. Email resourcelink@youngsurvival.org or call 877-972-1011.

      The Gift of Your Voice

      Are you a young woman surviving breast cancer ready to give back? If you answered yes, SurvivorLink is ready for you! Contact us about our online training to become a trained peer volunteer with YSC. Yes, train from the comfort of your own home on your own time. Newly diagnosed young women are looking to be matched with someone who shares a similar diagnosis, similar life experiences, or concerns. Email resourcelink@youngsurvival.org or call 877-972-1011.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      3 experts in this video
      3 experts in this video
      3 experts in this video
      3 experts in this video
      3 experts in this video
      3 experts in this video
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a woman with shoulder-length black hair wearing headphones and a white sweater
      Photo of a woman with brown hair and bangs, surrounded by a blue border
      Related Content

      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast

      Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

      Kristi Rosa
      May 31st 2025
      Article

      Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.


      Anatomical rendering of a breast with a tumor

      Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

      Caroline Seymour
      May 31st 2025
      Article

      Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

      Related Content

      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast

      Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

      Kristi Rosa
      May 31st 2025
      Article

      Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.


      Anatomical rendering of a breast with a tumor

      Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

      Caroline Seymour
      May 31st 2025
      Article

      Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.